Monopar Therapeutics (NASDAQ:MNPR) Director Sells 3,142 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) Director Raymond Anderson sold 3,142 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the transaction, the director directly owned 23,751 shares of the company’s stock, valued at approximately $2,654,649.27. This represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Trading Up 0.2%

Shares of MNPR traded up $0.22 on Thursday, reaching $113.94. 142,825 shares of the company’s stock traded hands, compared to its average volume of 220,179. The stock has a market cap of $764.77 million, a PE ratio of -52.51 and a beta of 1.47. The stock’s 50 day simple moving average is $104.63 and its two-hundred day simple moving average is $74.34. Monopar Therapeutics Inc. has a 52-week low of $32.77 and a 52-week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.02. Analysts forecast that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current year.

Hedge Funds Weigh In On Monopar Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in shares of Monopar Therapeutics during the 1st quarter valued at $673,000. Jane Street Group LLC bought a new stake in Monopar Therapeutics during the first quarter worth about $377,000. Geode Capital Management LLC increased its stake in shares of Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after purchasing an additional 48,379 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Monopar Therapeutics in the 2nd quarter worth approximately $209,000. Institutional investors own 1.83% of the company’s stock.

Wall Street Analyst Weigh In

MNPR has been the subject of several research reports. Morgan Stanley restated an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a research report on Monday, August 17th. Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Barclays reiterated an “overweight” rating and issued a $128.00 target price (up from $125.00) on shares of Monopar Therapeutics in a research note on Thursday, August 13th. Cantor Fitzgerald lowered shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $109.00 to $119.00 in a research note on Thursday, August 13th. Finally, Wall Street Zen cut shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $118.67.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.